HIV-Druginteractions.org

Cookies policy. You will see this message only once.
We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we’ll assume that
you’re happy to receive all cookies on this site. However, if you would like to, you can change your cookie settings at any time. Find out more.

Abstracts and Posters

Abstracts and posters arising from work carried out by the group are listed below. Please note that preliminary data may have been presented at meetings prior to publication of the final analysis. Posters and presentations are provided in Adobe Acrobat (pdf) format.

We would like to take this opportunity to thank all those who have participated in the various studies: their role is of great importance and does not always get the recognition it deserves.

Entries for the current year and three preceding years are shown here. Older entries can be found in the archive.

2010

Archive

2010

Population pharmacokinetic modelling of once-daily ritonavir-boosted darunavir in HIV-infected patients.
Dickinson L, Jackson AGA, Garvey LJ, Watson V, Khoo SH, Winston A, Boffito M, Davies GR, Back DJ. Tenth International Congress on Drug Therapy in HIV Infection, Glasgow, November 2010, abstract P184.

Population pharmacokinetic and pharmacogenetic analysis of nevirapine in hypersensitive and tolerant HIV-infected patients from Malawi.
Dickinson L, Chaponda M, Carr D, van Oosterhout JJ, Kumwenda J, Lalloo DG, Pirmohamed M, Heyderman R, Khoo SH. Tenth International Congress on Drug Therapy in HIV Infection, Glasgow, November 2010, abstract P181.

SLCO3A1 expression is a major determinant of atazanavir PBMC penetration in HIV-infected patients.
Siccardi M, D'Avolio A, Baietto L, Simiele M, Bonora S, Back DJ, Di Perri G, Owen A. Tenth International Congress on Drug Therapy in HIV Infection, Glasgow, November 2010, abstract P178.

Therapeutic drug monitoring (TDM) of atazanavir in pregnancy.
Else LJ, Jackson V, Brennan M, Breiden J, WeldridgeC, Coulter-Smith S, Back DJ, Khoo SH, Lambert J. Tenth International Congress on Drug Therapy in HIV Infection, Glasgow, November 2010, abstract P177.

Evaluating pharmacist involvement in HIV outpatient clinics: can medication histories, drug interaction checks and adherence assessments add benefit?
Seden K, Back DJ, Khoo SH Tenth International Congress on Drug Therapy in HIV Infection, Glasgow, November 2010, abstract P115.

Patients accessing HIV treatment via GUM services - what are the risks of the dual case note system?
Seden K, Mathew T, Friday G, Khoo S.

2nd Joint Conference of the British HIV Association and the British Association for Sexual Health and HIV, Manchester, April 2010, abstract P225.

Population pharmacokinetics of unboosted atazanavir and influence of the pregnane x receptor PXR.
Schipani A, Siccardi M, D'Avolio A, Baietto L, Bonora S, Davies G, Khoo S, Back D, di Perri G, Owen A.

2nd Joint Conference of the British HIV Association and the British Association for Sexual Health and HIV, Manchester, April 2010, abstract P16.

Therapeutic drug monitoring of lopinavir/ritonavir in pregnancy.
Lambert J, Else L, Jackson V, Breiden J, Gibbons S, Dickinson L, Back D, Brennan M, Connor EO, Boyle N, Fleming C, Coulter-Smith S, Khoo H.

2nd Joint Conference of the British HIV Association and the British Association for Sexual Health and HIV, Manchester, April 2010, abstract P12.

Altered plasma levels of nevirapine after commencing rifampicin containing TB regimens in Malawi.
Chaponda M, Nyirenda W, Watson V, White S, van Oosterhout JJ, Lalloo D, Pirmohamed M, Heyderman R, Mwandumda H, Khoo SH. 11th International Workshop on Clinical Pharmacology of HIV Therapy, Sorrento, April 2010, abstract 46.

Investigation of the association of CYP2B6 haplotypes with efavirenz plasma concentrations in a Chilean HIV cohort.
Carr D, La Porte CJL, Egan D, Pirmohamed M, Owen A, Cortes CP. 11th International Workshop on Clinical Pharmacology of HIV Therapy, Sorrento, April 2010, abstract 21.

A novel application of population pharmacokinetic analysis: simulating nevirapine dose adjustment according to CYP2B6 516G>T polymorphism.
Schipani A, Mahungu TW, Wyen C, Esser S, Brockmeyer NH, Khoo SH, Johnson M, Davies G, Owen A, and Back DJ. 11th International Workshop on Clinical Pharmacology of HIV Therapy, Sorrento, April 2010, abstract 20.

Intracellular pharmacokinetics of boosted and unboosted atazanavir in HIV infected patients.
Siccardi M, D'Avolio A, Simiele M, Sciandra M, Baietto L, Stefani FR, Agati S, Cusato J, Calcagno A, Owen A, Bonora S, Di Perri G. 11th International Workshop on Clinical Pharmacology of HIV Therapy, Sorrento, April 2010, abstract 17.

Evaluating the effect of gender on darunavir and ritonavir exposure in HIV infected subjects (a post-hoc analysis of the GRACE PK sub-study).
Else L, Liptrott N, Moss D, Dutton J, Fraser W, Kakude T, Mrus J, Back D. 11th International Workshop on Clinical Pharmacology of HIV Therapy, Sorrento, April 2010, abstract 11.

Application of population pharmacokinetic modelling to quantify the impact of SLCO1B1 521T>C polymorphism on lopinavir clearance.
Schipani A, Egan D, Davies G, Back DJ, Khoo SH, Owen A. 11th International Workshop on Clinical Pharmacology of HIV Therapy, Sorrento, April 2010, abstract 24.

Sequential population pharmacokinetic modelling of lopinavir and ritonavir: investigation of different dosing strategies.
Dickinson L, Boffito M, Back D, Else L, von Hentig N, Davies G, Khoo S, Pozniak A, Moyle G, Aarons L. 11th International Workshop on Clinical Pharmacology of HIV Therapy, Sorrento, April 2010, abstract 63.

Pharmacogenetics - upcoming applications to patient care.
Owen A. 17th Conference on Retroviruses and Opportunistic Infections, San Francisco, February 2010, abstract 113.

Genetic variants of ABCC10 are associated with kidney tubular dysfunction in patients treated with tenofovir-containing regimens.
Pushpakom S, Liptrott N, Rodríguez-Nóvoa S, Labarga P, Soriano V, Albalater M, Hopper-Borge E, Back D, Khoo S, and Owen A. 17th Conference on Retroviruses and Opportunistic Infections, San Francisco, February 2010, abstract 742.

A population pharmacokinetic model illustrates an association between a pregnane-X-receptor (PXR) polymorphism and boosted atazanavir clearance.
Schipani A, Siccardi M, Boffito M, D’Avolio A, Bonora S, Davies G, Khoo S, Back D, Di Perri G, and Owen A. 17th Conference on Retroviruses and Opportunistic Infections, San Francisco, February 2010, abstract 618.

Raltegravir is a substrate for the influx transporters OAT1 and PEPT1 and the efflux transporter Pgp but is not transported by OATP1A2, OATP1B1, OATP1B3, OCT1, NTCP, or PEPT2.
Moss D, Kwan WS, Liptrott N, Siccardi M, Anstee D, Khoo S, Back D, and Owen A. 17th Conference on Retroviruses and Opportunistic Infections, San Francisco, February 2010, abstract 613.

Integrating pharmacogenetics and population pharmacokinetic analysis: simulating the impact of CYP2B6 516G>T for 400 mg once daily nevirapine dosing.
Schipani A, Mahungu T, Wyen C, Esser S, Brockmeyer N, Khoo S, Johnson M, Davies G, Owen A, and Back D. 17th Conference on Retroviruses and Opportunistic Infections, San Francisco, February 2010, abstract 601.

Association of ABCC10 polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDS.
Liptrott N, Pushpakom S, Wyen C, Rockstroh J, Mauss S, Knechten H, Brockmeyer N, Hopper-Borge E, Back D, Owen A, and German Competence Network for HIV/AIDS. 17th Conference on Retroviruses and Opportunistic Infections, San Francisco, February 2010, abstract 600.

Solute carrier organic anion transporter 1B1 (SLCO1B1) mediates transport of maraviroc using a X. leavis model.
Siccardi M, Moss D, Kwan WS, D’Avolio A, Bonora S, Khoo S, Back D, Di Perri G, and Owen A. 17th Conference on Retroviruses and Opportunistic Infections, San Francisco, February 2010, abstract 599.